Pregledni rad

Pathophysiology of hormone-resistant prostate cancer

BORISLAV BELEV ; borislavbelev@gmail.com
TOMISLAV ŠIPIĆ

Sažetak

Androgen-deprivation therapy (ADT) has been for many years the cornerstone of metastatic prostate carcinoma (PC) treatment. It is very well documented that the majority of cancer cells in prostate gland remain androgen responsive what was the basis for androgen suppression in treatment. Nevertheless, after some time or sometimes initially, PCa cells become resistant to castration serum level of testosteron, because of some genetic and epigenetic changes that make them independent from hormone activation. There are two therories – the clonal theory and the adaptation theory of how some carcinoma cells become castration-resistant. It has been shown recently, that PCa cells can still use androgen receptor as a major signaling pathway, by activation of enzyme machinery or de novo production of androgen within the cells.

Ključne riječi

metastatic prostate cancer; androgen receptor (AR) castration-resistant prostate cancer (CRPC); androgen deprivation therapy (ADT)

Hrčak ID:

137761

URI

https://hrcak.srce.hr/137761

Datum izdavanja:

30.12.2014.

Posjeta: 1.346 *